# Characteristics and Predictors of Liver Injury in Cyclin-dependent Kinase Inhibitors 4/6 (CDK4/6)-Treated Patients With Advanced Breast Cancer

> **NCT06367335** · — · COMPLETED · sponsor: **University of Milano Bicocca** · enrollment: 128 (actual)

## Conditions studied

- DILI

## Interventions

- **DRUG:** Ribociclib, palbociclib, abemaciclib

## Key facts

- **NCT ID:** NCT06367335
- **Lead sponsor:** University of Milano Bicocca
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2022-06-01
- **Primary completion:** 2022-09-01
- **Final completion:** 2022-12-31
- **Target enrollment:** 128 (ACTUAL)
- **Last updated:** 2024-04-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06367335

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06367335, "Characteristics and Predictors of Liver Injury in Cyclin-dependent Kinase Inhibitors 4/6 (CDK4/6)-Treated Patients With Advanced Breast Cancer". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT06367335. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*